Solid‑Tumor CAR‑T: What China’s CLDN18.2 Filing Means for Patients (2025)
CAR‑T cell therapy has already changed the outlook for several blood cancers, delivering long remissions for some people after other options failed. For solid tumors, progress has been slower – until now. In 2025, China’s regulator accepted a New Drug Application (NDA) for a CAR‑T targeting CLDN18.2 in advanced gastric and gastroesophageal junction (GEJ) cancer. … Read more